The Atlanta Journal-Constitution

Pfizer says vaccine is OK for ages 5-11

Key question remains: Will parents support it if it gets FDA approval?

- Sarah Mervosh and Dana Goldstein

With Pfizer-biontech’s announceme­nt Monday that its COVID-19 vaccine had been shown to be safe and effective in low doses in children ages 5 to 11, a major question looms: How many parents will have it given to their children?

If authorized by the Food and Drug Administra­tion, the vaccine could be a game changer for millions of American families with young children and could help bolster the country’s response as the highly contagious delta variant of the coronaviru­s spreads.

There are about 28 million children ages 5 to 11 in the United States, far more than the 17 million adolescent­s ages 12 to 15 who became eligible when the Pfizer vaccine rolled out to that age group in May.

But it re m ains to be seen how widely the vaccine will be accepted for the younger group. Uptake among older children has lagged, and polling indicates reservatio­ns among a significan­t chunk of parents.

Lorena Tule-romain was up early Monday, getting ready to ferry her 7-year-old son to school

in Dallas, when she turned on the television and heard the news.

“I was like, ‘Oh, my gosh, this is exciting,’ “said Tule-romain, 32, who felt an initial surge of hopefulnes­s and relief. She has spent months living in limbo, declining birthday party invitation­s, holding off registerin­g her son for orchestra in school and even canceling a recent trip to see her son’s grandparen­ts in Atlanta.

A vaccine for her son, she said, could change all of that.

Tule-romain will be among those eagerly waiting to learn whether federal officials authorize the vaccine for the younger age group, a step that is expected to come first on an emergency-use basis, perhaps as soon as Halloween.

However the FDA rules, Michelle Goebel, 36, of Carlsbad, California, said she is nowhere near ready to vaccinate her children, who are 8, 6 and 3, against COVID-19.

Although Goebel said she had been vaccinated herself, she expressed worry about the risks for her children, in part because of the relatively small size of trials in children and the lack of long-term safety data so far. She said the potential risk from a new vaccine seemed to her to outweigh the benefit, because young children have been far less likely to become seriously sick from the virus than adults.

“We absolutely are not ready,” she said.

Only about 40% of children ages 12 to 15 have been fully vaccinated so far, compared with 66% of adults 18 and over, according to data from the Centers for Disease Control and Prevention. Polling indicates that parental openness to the vaccine for their children decreases with the child’s age.

About 20% of parents of 12- to 17-year-olds said they definitely did not plan to get their child vaccinated, according to polling by the Kaiser Family Foundation published last month. The “definitely not” group grew to about 25% among parents of children ages 5 to 11 and to 30% among parents of children under 5.

The Pfizer trial results were greeted enthusiast­ically by many school administra­tors and teachers organizati­ons, but are unlikely to lead to immediate policy changes.

“This is one huge step toward beating COVID and returning to normalcy. I don’t think it changes the conversati­on around vaccine requiremen­ts for kids,” said Randi Weingarten, president of the American Federation of Teachers, a national union.

Weingarten predicted there would not be widespread student vaccine mandates until the 2022-23 school year. She noted that parents and educators were still awaiting full FDA approval of vaccines for children ages 12 to 15 and that mandates for adults did not come until months after the shots first became available.

A significan­t barrier to child vaccinatio­n, she said, were widespread conspiracy theories about the shots impacting fertility.

“When people have these conversati­ons prematurel­y about requiremen­ts, it adds to the distrust,” she said.

Among the side effects scientists have been studying is myocarditi­s, an inflammati­on of the heart. In rare cases, the vaccine has led to myocarditi­s in young people. But a large Israeli study, based on electronic health records of 2 million people aged 16 and older, also found that COVID-19 is far more likely to cause the heart problems.

Only a single large school district — Los Angeles Unified — has mandated vaccinatio­n for those students already eligible for a shot, those 12 and older. On Monday, the district said it was not ready to respond to news about the Pfizer trial results for children under 12.

 ?? AP FILE DAVID GOLDMAN/ ?? Pfizer is awaiting FDA authorizat­ion for allowing its COVID-19 vaccine to be used to protect children ages 5-11 from the deadly coronaviru­s.
AP FILE DAVID GOLDMAN/ Pfizer is awaiting FDA authorizat­ion for allowing its COVID-19 vaccine to be used to protect children ages 5-11 from the deadly coronaviru­s.

Newspapers in English

Newspapers from United States